Announcements Trials
Browse Landscape

Status

No longer available 8Available 3Approved for marketing 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Interventions

tisagenlecleucel 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Available × Expanded_access × Lymphoma × Clear all
NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT01881334 2025-11-20

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Duke University

Available
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Adrenoleukodystrophy, Anemia, Aplastic, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Lymphoma, Metabolic Diseases, Myelodysplastic Syndromes, Thalassemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Kura Oncology, Inc.

Available
Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡